Does Ohio Medicaid Cover GLP-1 Weight Loss Drugs in 2026?
Ohio Medicaid covers GLP-1 drugs for type 2 diabetes with prior authorization but excludes them for weight loss in 2026 - here's what to do.
Curated articles and guides from health and wellness experts. Deep dives into the topics that matter most.
Ohio Medicaid covers GLP-1 drugs for type 2 diabetes with prior authorization but excludes them for weight loss in 2026 - here's what to do.
AHCCCS covers GLP-1 drugs for type 2 diabetes with prior authorization but excludes weight loss use, with narrow Wegovy exceptions for cardiovascular risk and MASH.
Iowa Medicaid covers GLP-1s for type 2 diabetes with prior authorization but excludes weight loss; Wegovy and Zepbound are covered only for CV-risk, OSA, or MASH.
The Wegovy pill costs $149 per month through April 15, 2026, as part of Novo Nordisk's launch pricing. After that, the regular price is $199 monthly for the 4mg dose, with higher doses costing more.
Foundayo is Eli Lilly's once-daily weight loss pill containing orforglipron, a non-peptide GLP-1 receptor agonist. Unlike other oral GLP-1 medications, you can take Foundayo with food and water at any time of day.
Wegovy 7.2mg is currently the strongest weight loss medication, delivering 20.7% average weight loss in clinical trials. Zepbound follows closely at 20-22%, while investigational retatrutide shows 24%+ results in Phase 3 trials.
The choice between GLP-1 pills and injections comes down to convenience versus effectiveness. Injections deliver superior weight loss results, while pills offer lifestyle flexibility and eliminate needle anxiety.
Clinical trial data shows clear efficacy differences between GLP-1 medications. Zepbound leads with 22.5% average weight loss, while newer high-dose formulations push results even higher.
In early 2026, deals were announced between the Trump administration and both Eli Lilly and Novo Nordisk to lower GLP-1 drug prices through the TrumpRX program. Here is what actually changed, what is available, and what the limitations are.
GLP-1 medications offer powerful benefits for women with PCOS beyond weight loss. These treatments address insulin resistance, restore ovulation, and improve fertility outcomes in 60-80% of patients with polycystic ovary syndrome.
Almost everyone on GLP-1 medication hits a plateau at some point. Weight stops dropping even though you are still taking the medication and following the plan. This is normal, expected, and manageable.
GLP-1 medications dramatically change how your body processes alcohol. Most patients experience increased intoxication from smaller amounts, while some lose interest in drinking altogether.
Recent studies show GLP-1 medications reduce depression and anxiety risk by 12-18% beyond their weight loss benefits. These mental health improvements often occur within weeks of starting treatment.
Getting oral Wegovy through telehealth platforms has become straightforward in 2026. Most patients can complete the entire process online, from consultation to prescription delivery.
GLP-1 medications cause rapid weight loss, but up to 40% of lost weight can be muscle mass without proper prevention strategies. Preserving muscle during GLP-1 treatment requires specific protein intake and resistance training protocols.